One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 223-229

  Bunck, Mathijs C ^a   Cornér, Anja ^b,c   Eliasson, Bjorn ^d   Heine, Robert J ^a,e   Shaginian, Rimma M ^e   Wu, Yan ^f   Yan, Ping ^f   Smith, Ulf ^d   Yki Järvinen, Hannele ^b   Diamant, Michaela ^a   Taskinen, Marja Riitta ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e ELI LILLY AND COMPANY   (United States)

^f AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Apo B48; Exenatide; Insulin glargine; Oxidative stress; Postprandial glucose; Postprandial lipids; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B48; CARBOHYDRATE; EXENDIN 4; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GLARGINE; MALONALDEHYDE; METFORMIN; PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

APOLIPOPROTEIN B-48; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EUROPE; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDES; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENOMS;

EID: 77956231970     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.04.024     Document Type: Article

References (27)

1. Tushuizen M.E., Diamant M., Heine R.J. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 2005, 81:1-6.
2. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
3. De Man F.H., Cabezas M.C., Van Barlingen H.H., Erkelens D.W., de Bruin T.W. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Investig 1996, 26:89-108.
4. Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137-2142.
5. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
6. Taskinen M.R., Packard C.J., Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 1990, 39:1017-1027.
7. Agardh C.D., Nilsson-Ehle P., Scherstén B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982, 5:322-325.
8. Taskinen M.R., Kuusi T., Helve E., Nikkilä E.A., Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988, 8:168-177.
9. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
10. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Int Med 2005, 143:559-569.
11. Schwartz S.L., Ratner R.E., Kim D.D., et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008, 30:858-867.
12. Bunck M.C., Diamant M., Cornér A., et al. One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized controlled trial. Diabetes Care 2009, 32:762-768.
13. van de Kerkhof J., Schalkwijk C.G., Konings C.J., et al. Nepsilon-(carboxymethyl) lysine. Nepsilon-(carboxyethyl) lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004, 19:910-916.
14. Scheffer P.G., Bakker S.J., Heine R.J., Teerlink T. Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. Clin Chem 1997, 43:1904-1912.
15. Hsieh J., Hayashi A.A., Webb J., Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl 2008, 9:7-13.
16. Qin X., Shen H., Liu M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949.
17. Hsieh J., Longuet C., Baker C.L., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
18. Cianflone K., Paglialunga S., Roy C. Intestinally derived lipids: metabolic regulation and consequences--an overview. Atheroscler Suppl 2008, 9:63-68.
19. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
20. Cervera A., Wajcberg E., Sriwijitkamol A., et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008, 294:E846-E852.
21. Ionut V., Zheng D., Stefanovski D., Bergman R.N. Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab 2008, 295:E269-E277.
22. Mari A., Nielsen, Nanayakkara, DeFronzo R.A., Ferrannini E., Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006, 38:838-844.
23. Mari A., Degn, Brock, Rungby, Ferrannini, Schmitz Effects of the long-acting human GLP-1 analogue liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007, 30:2032-2033.
24. Mari A., Scherbaum W.A., Nilsson P.M., et al. Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008, 93:103-109.
25. Bonuccelli S., Muscelli E., Gastaldelli A., et al. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab 2009, 297:E532-E537.
26. Heine R.J., Balkau B., Ceriello A., Del Prato S., Horton E.S., Taskinen M.R. What does postprandial hyperglycaemia mean?. Diab Med 2004, 21:208-213.
27. Shen L., Han J., Yushmanove I., Bruce S., Porter L. Cardiovascular safety of exenatide BID: an integrated analysis from long-term controlled clinical trials in subjects with type 2 diabetes (Abstract). Diabetes 2009, 58(Suppl. 1):A96-A97.